Core Viewpoint - China's innovative pharmaceutical industry is entering a period of significant achievement, with 76 innovative drugs approved in 2025, over 80% of which are domestically produced, and total licensing transaction amounts exceeding $130 billion, setting a historical record [1] Group 1: Company Transformation - Heng Rui Medicine, originally a generics giant, has successfully transitioned to innovative drugs, with innovative drug revenue surpassing 60% of total revenue [1] - The company faced challenges starting in 2020 when the implementation of national drug procurement policies marked the end of high-profit margins for generics, leading to a decline in revenue and profit in 2021 and 2022 [2] - The management recognized the necessity for transformation due to shrinking profit margins in traditional generics and increasing competition, prompting a shift towards clinically differentiated innovations [2] Group 2: Leadership and Strategy - After stepping back for a year and a half, Sun Piaoyang returned to lead Heng Rui Medicine in July 2021, focusing on innovation and international expansion [3][4] - Upon his return, Sun made significant cuts to generics R&D projects, reallocating resources to innovative drug development, and expanded the R&D pipeline into diverse therapeutic areas [4] - The company adopted a differentiated R&D strategy, achieving notable successes in the ADC platform with over ten new ADC molecules approved for clinical trials [4] Group 3: Operational Changes - The company underwent a major restructuring, reducing the sales force by nearly 50% from 17,100 in 2020 to 8,910 by the end of 2024, while also streamlining its organizational structure [5][6] - The shift from a marketing-driven to a research-driven model was a key focus of the internal transformation [6] Group 4: Internationalization Efforts - In 2024, domestic revenue accounted for 86.81% of total revenue, while international revenue was only 2.56%, highlighting the need for greater international presence [6] - The "borrow a boat to go to sea" strategy was implemented to enhance international competitiveness, resulting in significant overseas licensing deals, including five overseas BD authorizations in 2023 totaling over $4 billion [6][7] - By 2025, Heng Rui had achieved 13 overseas licensing collaborations with a total transaction amount nearing $14 billion, further diversifying its international partnerships [7] Group 5: Financial Performance - In the first half of 2025, revenue from innovative drugs and licensing exceeded 60%, reaching 60.66%, while international revenue increased to 2.568 billion yuan, accounting for 16.29% of total revenue [7]

Core Viewpoint - Kaliera, a subsidiary of HengRui Medicine, is strategically positioned in the global weight loss market, focusing on innovative GLP-1 drugs to address the unmet medical needs of over 1 billion obese individuals and related complications [4][9]. Group 1: Company Overview - Kaliera was established in October 2024, with a clear mission to treat obesity as a chronic disease requiring long-term management rather than a mere lifestyle issue [4]. - The company has raised a total of $900 million through two funding rounds, attracting investments from top-tier life science firms like Bain Capital and Atlas Venture [4]. - The management team consists of experienced executives from multinational pharmaceutical and biotech companies, ensuring effective global clinical development and regulatory communication [4]. Group 2: Product Pipeline - Kaliera's core pipeline includes three GLP-1 related products: HRS-9531 (a GLP-1/GIP dual agonist), HRS-7535 (a small molecule GLP-1 receptor agonist), and HRS-4729 (a GLP-1/GIP/GCG tri-agonist) [6]. - HRS-9531 is highlighted as the most promising asset, having demonstrated significant weight loss results in clinical trials, achieving an average weight reduction of 23.6% in a 36-week study with the 8mg dose [7][8]. Group 3: Clinical Development - The ongoing global Phase III clinical project, KaiNETIC, for HRS-9531 aims to explore the upper limits of weight loss effects with a more aggressive design, including higher dosing than previous trials [8]. - The timeline for international expansion is clear, with plans to initiate Phase II trials for oral HRS-9531 and KAI-7535 by 2026, and key data for HRS-9531 expected by 2028 [8]. Group 4: Market Positioning - Kaliera's emergence signifies a shift for Chinese innovative drug companies from mere participants to rule-makers in the global market, leveraging HengRui's long-term R&D capabilities [9]. - The company aims to find a unique global path for Chinese innovation in the competitive landscape of weight loss medications, focusing on efficacy, safety, and multi-target combinations [9].

[Table_Page] 投资策略|专题报告 2026 年 2 月 8 日 证券研究报告 [Table_Summary [Table_Title] ] 春节前后，港股如何反应？ ——港股市场策略展望 报告摘要： （4）港股天量 IPO 对市场影响不大，影响主要在于 IPO 过后 6 个月 的解禁高峰。典型的例如 11 年年中、15 年下半年、19 年 3 月、21 年 二季度、22 年年中，解禁潮都与港股下跌出现在相似时间段。26 年 3 月主要是有色金属（紫金黄金国际、南山铝业国际）+茶饮（蜜雪冰城） 的解禁潮，中大型规模公司的解禁规模 872 亿港元，高于去年年末的 解禁小高峰。由于港股通账户并不能够参与打新，享受稀缺性公司的 上市红利，却需要承受限售股解禁带来的风险，这可能确实是南向资 金对于 2026 年港股的主要担忧之一。 | [分析师： Table_Author]刘晨明 | | | --- | --- | | | SAC 执证号：S0260524020001 | | | SFC CE No. BVH021 | | | 010-59136616 | | | liuchenming@gf.com.cn ...

Group 1 - The total value of the top 500 companies in China increased by 21 trillion yuan (38%), reaching 77 trillion yuan, with an average value growth of 41.5 billion yuan, now at 1.53 trillion yuan [1][2] - The entry threshold for the list rose to 34 billion yuan, an increase of 7.5 billion yuan from the previous year, marking a historical high [1][2] - The technology sector continues to be a growth engine, with significant increases in the number and market value of companies in semiconductor, biomedicine, artificial intelligence, and new energy sectors [1][2] Group 2 - Nearly 40% of this year's listed companies were not on the list four years ago, with new entrants primarily from consumer electronics, AI computing, and new energy sectors [2] - The semiconductor industry surpassed the life sciences sector to become the second-largest industry in the list, with TSMC leading the growth [3] - Notable semiconductor companies include TSMC, which saw a value increase of 3.5 trillion yuan, and Cambrian, which grew by 370 billion yuan [3] Group 3 - The new energy sector also performed well, with CATL's value increasing by 690 billion yuan, and other companies like Sungrow and EVE Energy showing significant growth [4] - The Shanghai region had 57 companies on the list, an increase of 7 from the previous year, making it the city with the fastest growth in the number of listed companies [10] - Shanghai is a key research and development hub, with 101 companies establishing their main R&D bases there, reflecting its strong innovation capabilities [10][11] Group 4 - The STAR Market (科创板) has a strong presence in the list, with 45 companies, showcasing the focus on hard technology sectors like semiconductors and biomedicine [6][7] - The semiconductor sector is particularly prominent among STAR Market companies, with many of the highest-valued startups in this field [8] - The overall trend indicates that STAR Market companies are in a high-growth phase, aligning with the broader trend of nearly 40% of this year's companies being new entrants [9]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, indicating a significant advancement in the treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutations [1] Group 1 - The HRS-4642 injection is used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment [1]

Group 1 - Core viewpoint: Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic drugs by the National Medical Products Administration [1] - Drug name: HRS-4642 injection, application number: CXHL2400083, classified as a Class 1 chemical drug [2] - Proposed indication: To be used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutation [2] Group 2 - Application date for HRS-4642: December 24, 2025 [2] - The application meets the requirements of the Drug Registration Management Measures and the announcement regarding the breakthrough therapeutic drug review procedures [2]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, indicating a significant advancement in the treatment of advanced or metastatic pancreatic cancer with KRAS G12D mutations [1] Group 1 - The HRS-4642 injection is used in combination with gemcitabine and albumin-bound paclitaxel for first-line treatment [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年2月6日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 证券代码：600276 证券简称：恒瑞医药 公告编号：临2026-023 ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

Core Viewpoint - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration, targeting advanced or metastatic pancreatic cancer with KRAS G12D mutation [1] Group 1: Product Development - HRS-4642 is a self-developed KRAS G12D inhibitor in a liposomal formulation [1] - The product is intended for use in combination with gemcitabine and albumin-bound paclitaxel as a first-line treatment [1] - Currently, there are no similar drugs approved for market domestically or internationally [1] Group 2: Market Context - Pancreatic cancer is a common malignant tumor of the digestive system, with 510,566 new cases reported globally in 2022, ranking 12th among malignant tumors [1] - The disease resulted in 467,005 deaths in 2022, making it the 6th leading cause of cancer-related deaths, accounting for approximately 5% of global cancer mortality [1]